Netarsudil ophthalmic solution shows positive phase 2 results in Japanese-American population

A pilot phase 2 trial showed Aerie Pharmaceuticals’ netarsudil ophthalmic solution lowered IOP in a Japanese-American population, according to a press release.
Two dose concentrations of netarsudil ophthalmic solution, known as Rhopressa (netarsudil ophthalmic solution 0.02%) in the United States, were studied in 40 Japanese-American subjects in accordance with the requirements of Japan’s Pharmaceuticals and Medical Devices Agency to support potential regulatory submission, the release said.
Patients with an average baseline IOP of 18.3 mm Hg received netarsudil ophthalmic solution

Full Story →